Current Advances in the Treatment of BRAF-Mutant MelanomaHima Patel, Joan T. Garrett|Cancers|2020Cited by 172
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant MelanomaHima Patel, Joan T. Garrett|Cancers|2021Cited by 33
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cellsHima Patel, Joan T. Garrett|Anti-Cancer Drugs|2023Cited by 6